Jan 24 (Reuters) - Celgene Corp CELG.O
* Celgene Inc says Health Canada has expanded indication for REVLIMID in multiple myeloma
* Celgene Corp says REVLIMID in combination with dexamethasone, is indicated for treatment of multiple myeloma patients who are not eligible for stem cell transplant Source text for Eikon: Further company coverage: CELG.O